Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia - Research report from Molecular Cancer.

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. - study out of Austria found some clues about how these kinase inhibitors work in the metabolism.

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. - British study concluded the predominant effect of the drug is to prevent proliferation of cancer (rather than killing the malignant cells.)

M.D. Anderson evaluation report

Strategies for overcoming imatinib resistance in chronic myeloid leukemia. - University of Michigan study

Response dynamics to nilotinib depend on the type of BCR-ABL mutations in patients with chronic myelogenous leukemia (CML) after imatinib failure. - American Society of Clinical Oncology

A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib. - Journal of Clinical Oncology